Pharma Stock in Motilal Oswal’s Portfolio Pick Delivers 155% Profit CAGR in 3 Years

Synopsis: A US-focused pharma formulations player has posted a blockbuster March quarter, with profit more than doubling year-on-year. Backed by a stellar 3-year profit CAGR, a fresh CNS acquisition, and rising specialty product contribution, the company’s growth story appears far from over.

Strong earnings momentum continues to build for this pharmaceutical formulations company, which caters largely to the regulated US market. The latest quarterly numbers show broad-based revenue growth, expanding margins, and a sharp jump in profitability, backed by a three-year compounded profit growth rate of 155%. With a recent domestic acquisition and steady product approvals, the company is positioning itself for the next leg of growth.

Shares of Rubicon Research Limited, with a market capitalization of Rs.23,633 crore, closed at Rs.1,431.4 on Friday. The stock currently trades at a P/E ratio of 114.4.

Motilal Oswal’s Recent Pick

According to the brokerage report, Rubicon Research has joined Motilal Oswal’s portfolio within the healthcare space, alongside Apollo Hospitals. While Apollo is expected to benefit from improving profitability across its hospital and digital healthcare businesses, this company is expected to deliver steady earnings growth supported by its research and development engine.

A Standout Compounding Track Record

The headline number that catches attention is the company’s three-year compounded profit growth of 155%, alongside a three-year compounded sales growth of 65%. Even on a five-year basis, the numbers remain strong, with sales compounding at 41% and profit at 52%. On a trailing twelve-month (TTM) basis, sales growth stands at 37% while profit growth comes in at 85%, indicating that the pace of earnings expansion, while still elevated, has been even sharper than revenue growth over the recent past.

This pattern, where profit compounding consistently outstrips sales compounding, points to meaningful operating leverage and margin expansion playing out in the business over the last few years.

Q4 Results Show Broad-Based Growth

The company reported consolidated revenue from operations of ₹513.9 crore in Q4 FY26, up 43.5% year-on-year from ₹358.1 crore in Q4 FY25. EBITDA for the quarter came in at ₹121.3 crore, a 67.2% jump, while profit after tax more than doubled to ₹76.8 crore from ₹36.2 crore a year earlier, translating into 111.8% growth. Fully diluted EPS rose 97% to ₹4.60.

For the full year FY26, consolidated revenue stood at ₹1,754 crore, up 36.6% over FY25’s ₹1,284.3 crore. EBITDA grew 52.3% to ₹408 crore, and PAT climbed 83.6% to ₹246.7 crore, with EPS at ₹15.31 for the year. Operating EBITDA margin for FY26 stood at 22.8%, up from 20.6% in the previous year, while pre-tax return on average capital employed (ROACE) improved sharply to 36% from 30%.

Management attributed the growth to broad-based revenue traction across its product portfolio, with the top five products contributing 39% of Q4 revenue and the top ten contributing 57% – a marked reduction in product concentration compared to earlier years. USD revenue for the quarter came in at $56 million, up 35% year-on-year, with nearly 98% of total revenue denominated in US dollars.

Specialty Portfolio and R&D Push

A key driver of the Rubicon’s margin profile has been its shift toward specialty and differentiated products. These products, defined as those facing zero or at most one competitor for at least a year after launch, contributed 32.3% of total gross profit in FY26, up from just 13% two years earlier. The company’s specialty business has also turned profit-positive at the group level.

R&D spending remains a strategic priority, with expenses at 11.6% of operating revenue in Q4 FY26. Management noted that incremental revenue generated per rupee of lagging R&D spend has been steadily improving, rising from 3.3x in FY24 to 5.9x in FY26, reflecting improving productivity of research investments. The company received 12 product approvals in FY26, and had 24 products under review with the US FDA as of March 31, 2026, with a commercialisation rate of over 91% for approved products.

Recent Acquisition Expands Domestic Footprint

In April 2026, Rubicon Research acquired an 85% stake in a CNS-focused Indian formulations business for approximately ₹176 crore, on an enterprise value of ₹200 crore, cash and debt free. The acquired entity brings a portfolio of 60 CNS brands, roughly 160 sales representatives, and a presence across more than 5,000 pharmacies and 600 stockists in India. The company plans to layer its R&D capabilities, differentiated products, and stronger balance sheet onto this platform in a phased manner, aiming first to build growth drivers before shifting focus to profitability.

About the Company

Rubicon Research Ltd. is an R&D-driven pharmaceutical formulations, manufacturing, and marketing business focused on regulated markets, primarily the United States. It operates a portfolio spanning specialty products, drug-device combinations, and complex generics, supported by manufacturing sites for oral solids, oral liquids, and nasal spray products, along with R&D facilities across India and Canada.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock in Motilal Oswal’s Portfolio Pick Delivers 155% Profit CAGR in 3 Years appeared first on Trade Brains.